Exchange Traded Concepts LLC Boosts Stock Position in Novo Nordisk A/S $NVO

Exchange Traded Concepts LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 22.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,469 shares of the company’s stock after purchasing an additional 19,516 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Novo Nordisk A/S were worth $5,963,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after buying an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after acquiring an additional 187,789 shares in the last quarter. Kingstone Capital Partners Texas LLC lifted its position in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after acquiring an additional 10,001,898 shares in the last quarter. Sustainable Growth Advisers LP boosted its stake in Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after purchasing an additional 649,390 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after purchasing an additional 47,430 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 7.4%

Shares of NVO opened at $51.66 on Wednesday. The firm has a market cap of $230.65 billion, a P/E ratio of 15.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The company has a 50 day simple moving average of $49.55 and a two-hundred day simple moving average of $57.16.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on NVO. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $53.33.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of oral Wegovy — market catalyst: The FDA cleared the first oral GLP‑1 pill for weight management, giving Novo a first‑mover commercial advantage and a path to regain share lost to Eli Lilly. Read More.
• Positive Sentiment: Launch plan and pricing expected to drive near‑term sales: Novo plans a U.S. launch in early January with an introductory cash price (~$149/month for starting dose), targeting the large self‑pay market. This gives investors a near-term revenue catalyst. Read More.
• Positive Sentiment: Unusual options activity and strong volume — investor conviction: Large call buying and much higher-than-normal trading volume indicate speculative and directional interest tied to the approval. Read More.
• Positive Sentiment: Analyst commentary supportive: Some analysts (e.g., HSBC cited in recent coverage) see Novo as having an edge over Eli Lilly after getting to market first with an oral option. Read More.
• Neutral Sentiment: ETF and sector flows may amplify moves: Approval has renewed interest in health‑care/GLP‑1 ETFs, which could lift peers and the sector irrespective of Novo’s fundamentals. Read More.
• Neutral Sentiment: Demand and reimbursement are untested for a cash‑market pill: Novo will initially push the pill into self‑pay channels, so uptake and conversion to covered prescriptions remain uncertain and could temper sales growth. Read More.
• Negative Sentiment: Competitive risk from Eli Lilly and others: Analysts warn Lilly’s oral development and its strong injectable momentum remain a material competitive threat; timing of Lilly’s response could cap upside. Read More.
• Negative Sentiment: Regulatory/generic noise in other markets: Separate regulatory delays for generics and local reimbursement issues (e.g., Canada) highlight ongoing access and pricing risks outside the U.S. Read More.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.